Avant Technologies Inc Stock Price, News & Analysis

Avant Technologies Inc. (OTCQB:AVAI) and its partner Ainnova Tech have expanded their joint venture agreement to include a global license for developing and marketing Ainnova's technology portfolio. The partnership, through Ai-nova Acquisition Corp. (AAC), will focus on advancing Ainnova's Vision AI platform and proprietary retinal camera technology.

The Vision AI platform can detect diabetic retinopathy and other retinal diseases, as well as non-retinal conditions like cardiovascular disease, prediabetes, type 2 diabetes, fatty liver diseases, and chronic kidney disease using retinal scans. Under the amended agreement, AAC will have global SaaS and hardware commercialization opportunities with opticians and eye care centers.

This expansion comes ahead of Ainnova's meetings with the FDA to prepare for a planned clinical trial of its Vision AI platform. Ainnova will request a pre-submission meeting for guidance on clinical testing for diabetic retinopathy detection, leading to an FDA 510(k) submission. For Avant, these FDA interactions will help define the budget for the regulatory process and are important for marketing the technology in the United States.

Avant Technologies (OTCQB:AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech and board member of Ai-nova Acquisition Corp (AAC), will be a featured speaker at the 2025 AI Revolution in Healthcare Summit in Dubai on February 15-16.

Vargas will address experts and investors about the clinical adoption of AI in healthcare, focusing on how it improves diagnostics and expands access to underserved communities. His presentation will cover key adoption drivers like investments in telemedicine and AI-powered imaging, while discussing challenges in data standardization, regulatory compliance, and workforce training.

As a panelist, he will participate in discussions about ethics in healthcare AI deployment, including data privacy, algorithmic bias, transparency in AI decision-making, and regulatory compliance across regions.

Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have selected Fortrea as their Contract Research Organization (CRO) for upcoming FDA clinical trials. The trials will focus on seeking FDA approval for Ainnova's Vision AI platform, specifically for early detection of diabetic retinopathy.

Fortrea will assist in requesting a pre-submission FDA meeting expected in late March/early April 2025, followed by clinical studies and an FDA 510(k) submission. Through their joint venture, Ai-nova Acquisition Corp. (AAC), the companies hold licensing rights for the technology portfolio in the U.S., Canada, and Europe.

Additionally, Ainnova plans to seek FDA clearance for four recently acquired algorithms targeting early detection of cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease, and chronic kidney disease.

Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech have secured exclusive licenses for four AI-driven healthcare algorithms from a major Asian healthcare institution. These algorithms, validated with over 2 million patient data points, focus on early detection of cardiovascular risk, prediabetes, Type 2 diabetes, fatty liver disease, and chronic kidney disease. The solutions will be integrated into Ainnova's VisionAI platform, with plans to launch in Latin American markets and pursue FDA clearance in 2025 for US market entry.

The broader AI market reached $184 billion in 2024, showing a $50 billion increase from 2023, with projections to exceed $826 billion by 2030. Healthcare remains a critical application area for AI, focusing on improving diagnostics, personalizing treatment plans, and optimizing patient care.

Avant Technologies (OTCQB: AVAI) and partner Ainnova Tech have secured exclusive licensing for 4 AI-driven disease detection algorithms from a major Asian healthcare institution. The algorithms, validated across 2+ million patients, target early detection of cardiovascular risk, prediabetes/Type 2 diabetes, fatty liver disease, and chronic kidney disease.

These solutions will integrate with Ainnova's VisionAI platform and existing retinal disease detection tools. The partnership plans to launch in Latin American markets and aims for FDA clearance in 2025 for U.S. market entry. The algorithms show impressive performance metrics, including 90%+ precision in coronary artery disease risk prediction and 88%+ accuracy in liver fibrosis screening.

Avant Technologies (OTCQB: AVAI) partner, Ainnova Tech, has announced a strategic alliance with Roche and Salud 360 to launch a pilot program combating diabetic retinopathy in Costa Rica. The program will utilize Ainnova's AI technology and non-mydriatic fundus cameras to analyze retinal images for early detection of the disease.

The initiative targets Costa Rica, where diabetes affects 10.4% of adults, with 20-40% of diabetic patients developing diabetic retinopathy. The program aims to prevent blindness through early detection, as 80% of diabetes-related blindness cases are preventable with timely intervention. If successful, Avant and Ainnova plan to expand the program to the United States, Canada, and Europe through their joint venture, Ai-nova Acquisition Corp (AAC).

Avant Technologies (OTCQB: AVAI) and Ainnova Tech announced plans to advance a proprietary low-cost retinal camera integrated with Ainnova's Vision AI software platform. The combined technology will provide retinal scans for early disease detection, including diabetic retinopathy, glaucoma, macular edema, and other conditions. The system will be marketed as a Software as a Service (SaaS) + retinal camera package through Ai-nova Acquisition Corp (AAC), targeting primary care clinics, insurance companies, opticians, and pharmacies with a pay-per-use model. AAC holds licensing rights for North America and Europe.

Avant Technologies (OTCQB: AVAI) and Ainnova Tech have formed a joint venture called Ai-nova Acquisition Corp (AAC) to advance early disease detection using AI. The partnership focuses on commercializing Ainnova's VisionAI platform and Versatile Retinal Cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. Ainnova will contribute its technology portfolio while Avant will handle capital requirements. The technology addresses a critical healthcare gap, as over 500 million people live with diabetes globally, and 30% may develop diabetic retinopathy. The AI in healthcare market is projected to grow from $6.9 billion to $67.4 billion by 2027.

Avant Technologies (OTCQB:AVAI) is accelerating the development of an AI-powered platform to revolutionize patient care in the healthcare industry. The platform aims to transform care delivery, optimize clinical workflows, and enhance decision-making for healthcare professionals. Key features include:

• Predictive Health Analytics for early detection of health issues
• Personalized Treatment Plans utilizing AI to analyze patient data
• Advanced Data Integration for secure access to patient information

The company is focusing on creating a secure, scalable AI infrastructure that integrates with existing healthcare systems. Avant's platform aims to bridge the gap between providers and underserved communities through AI-driven telemedicine capabilities. The company is actively seeking partnerships in the healthcare space to bring its AI-powered solutions to market.